The inherent genetic effects were not established between type 2 diabetes (T2DM) and Alzheimer's disease and related dementia (ADRD).
Objective
We aimed to investigate the association between T2DM and ADRD by integrating T2DM polygenic risk score (PRS) and applying matching in every subgroup.
Methods
We utilized UK Biobank First-occurrences datasets. T2DM were 1:1 matched to non-T2DM using propensity scores generated by 8 covariates; age at diagnosis, sex, cerebrovascular disease, ischemic heart disease, hypertensive disorders, lipid disorders, obesity, and mood disorders. T2DM PRS was additionally matched in T2DM PRS matched analysis. Subgroup analyses by age at diagnosis, sex, and APOE4 genotype were performed with the same matching criteria within each subgroup. Cox proportional hazard and Fine & Gray competing risk model were utilized.
Results
In T2DM PRS unmatched cohort, 24,583 T2DM were 1:1 matched to non-T2DM. The mean age at diagnosis was around 62 years old, with females constituting around 40%. Up to 25-year follow-up, ADRD rate/1000 person-years was 0.88 versus 1.52 (Non-T2DM versus T2DM); PRS unmatched (cHR: 1.72, 95% CI: 1.46–2.03) and matched (cHR:1.75, 95% CI: 1.47–2.09). Except for older age onset (≥75 years), the other subgroups demonstrated significantly increased ADRD risks in T2DM. T2DM PRS was higher in non-ADRD group across all subgroups. Contrarily, T2DM PRS was higher in ADRD in younger onset group (<55 years).
Conclusions
T2DM is one of the strong risk factors of ADRD but genetic T2DM effect does not contribute to ADRD risk. However, a genetic link might be present in younger age onset group.
BrandsABiesselsGde HaanE, et al.The effects of type 1 diabetes on cognitive performance: a meta-analysis. Diabetes Care2005; 28: 726–735.
4.
BiesselsGStaekenborgSBrunnerE, et al.Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol2006; 5: 64–74.
5.
AhmedSMahmoodZZahidS. Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurol Sci2015; 36: 1763–1769.
6.
BancksMCarnethonMJacobsDJr, et al.Fasting glucose variability in young adulthood and cognitive function in middle age: the Coronary Artery Risk Development in Young Adults (CARDIA) study. Diabetes Care2018; 41: 2579–2585.
7.
SunYMaCSunH, et al.Metabolism: a novel shared link between diabetes mellitus and Alzheimer's disease. J Diabetes Res2020; 2020: 4981814.
8.
de la MonteSMWandsJR. Alzheimer's disease is type 3 diabetes—evidence reviewed. J Diabetes Sci Technol2008; 2: 1101–1113.
9.
GudalaKBansalDSchifanoF, et al.Diabetes mellitus and risk of dementia: a meta-analysis of prospective observational studies. J Diabetes Investig2013; 4: 640–650.
10.
HaroonNAustinPShahB, et al.Risk of dementia in seniors with newly diagnosed diabetes: a population-based study. Diabetes Care2015; 38: 1868–1875.
11.
JansonJLaedtkeTParisiJ, et al.Increased risk of type 2 diabetes in Alzheimer disease. Diabetes2004; 53: 474–481.
12.
HaanM. Therapy Insight: type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol2006; 2: 159–166.
13.
MoranCPhanTChenJr, et al.Brain atrophy in type 2 diabetes: regional distribution and influence on cognition. Diabetes Care2013; 36: 4036–4042.
14.
BrundelMKappelleLBiesselsG. Brain imaging in type 2 diabetes. Eur Neuropsychopharmacol2014; 24: 1967–1981.
15.
WeiseCChenKChenY, et al.Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment. Neuroimage Clin2018; 20: 286–296.
16.
AnYVarmaVRVarmaS, et al.Evidence for brain glucose dysregulation in Alzheimer's disease. Alzheimers Dement2018; 14: 318–329.
17.
SattarNRawshaniAFranzénS, et al.Age at diagnosis of type 2 diabetes mellitus and associations with cardiovascular and mortality risks. Circulation2019; 139: 2228–2237.
18.
AndrewsSJFulton-HowardBO'ReillyP, et al.Causal associations between modifiable risk factors and the Alzheimer's phenome. Ann Neurol2021; 89: 54–65.
19.
JamesSWongATillinT, et al.The effect of mid-life insulin resistance and type 2 diabetes on older-age cognitive state: the explanatory role of early-life advantage. Diabetologia2019; 62: 1891–1900.
20.
ChungSKimMKimJ, et al.Association of type 2 diabetes GWAS loci and the risk of Parkinson's and Alzheimer's diseases. Parkinsonism Relat Disord2015; 21: 1435–1440.
21.
ØstergaardSMukherjeeSSharpS, et al.Associations between potentially modifiable risk factors and Alzheimer disease: a Mendelian randomization study. PLoS Med2015; 12: e1001841. discussion e1001841.
22.
WalterSMardenJKubzanskyL, et al.Diabetic phenotypes and late-life dementia risk: a mechanism-specific Mendelian randomization study. Alzheimer Dis Assoc Disord2016; 30: 15–20.
23.
LitkowskiELogueMZhangR, et al.A diabetes genetic risk score is associated with all-cause dementia and clinically diagnosed vascular dementia in the Million Veteran Program. Diabetes Care2022; 45: 2544–2552.
24.
DybjerEKumarANäggaK, et al.Polygenic risk of type 2 diabetes is associated with incident vascular dementia: a prospective cohort study. Brain Commun2023; 5: fcad054.
25.
KamalABiesselsGGispenW, et al.Synaptic transmission changes in the pyramidal cells of the hippocampus in streptozotocin-induced diabetes mellitus in rats. Brain Res2006; 16: 1073–1074.
26.
KheraAChaffinMZekavatS, et al.Whole-genome sequencing to characterize monogenic and polygenic contributions in patients hospitalized with early-onset myocardial infarction. Circulation2019; 139: 1593–1602.
27.
ThompsonDWellsDSelzamS, et al.A systematic evaluation of the performance and properties of the UK Biobank Polygenic Risk Score (PRS). PLoS One2024; 19: e0307270.
28.
WilkinsonTSchnierCBushK, et al.Identifying dementia outcomes in UK Biobank: a validation study of primary care, hospital admissions and mortality data. Eur J Epidemiol2019; 34: 557–565.
29.
SeshadriSWolfPBeiserA, et al.Stroke risk profile, brain volume, and cognitive function: the Framingham Offspring Study. Neurology2004; 63: 1591–1599.
30.
EliasMSullivanLEliasP, et al.Atrial fibrillation is associated with lower cognitive performance in the Framingham offspring men. J Stroke Cerebrovasc Dis2006; 15: 214–222.
31.
NishtalaAPiersRHimaliJ, et al.Atrial fibrillation and cognitive decline in the Framingham Heart Study. Heart Rhythm2018; 15: 166–172.
32.
liasMFEliasPKSullivanLM, et al.Lower cognitive function in the presence of obesity and hypertension: the Framingham Heart Study. Int J Obes Relat Metab Disord2003; 27: 260–268.
BanoG. Glucose homeostasis, obesity and diabetes. Best Pract Res Clin Obstet Gynaecol2013; 27: 715–726.
35.
MendezM. Degenerative dementias: alterations of emotions and mood disorders. Handb Clin Neurol2021; 183: 261–281.
36.
HebertLEWeuveJScherrPA, et al.Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology2013; 80: 1778–1783.
37.
BarnesLWilsonRBieniasJ, et al.Sex differences in the clinical manifestations of Alzheimer disease pathology. Arch Gen Psychiatry2005; 62: 685–691.
38.
AlmeidaRSchultzSAustinB, et al.Effect of cognitive reserve on age-related changes in cerebrospinal fluid biomarkers of Alzheimer disease. JAMA Neurol2015; 72: 699–706.
39.
MyersRSchaeferEWilsonP, et al.Apolipoprotein E epsilon4 association with dementia in a population-based study: the Framingham study. Neurology1996; 46: 673–677.
40.
SchoenfeldD. Partial residuals for the proportional hazards regression model. Biometrika1982; 69: 239–241.
41.
ZhangZKimHLonjonG, et al.Balance diagnostics after propensity score matching. Ann Transl Med2019; 7: 10.
42.
BunnFBurnAGoodmanC, et al.Comorbidity and dementia: a scoping review of the literature. BMC Med2014; 12: 014–0192.
43.
GottesmanRAlbertMAlonsoA, et al.Associations between midlife vascular risk factors and 25-year incident dementia in the Atherosclerosis Risk in Communities (ARIC) cohort. JAMA Neurol2017; 74: 1246–1254.
44.
RönnemaaEZetheliusBLannfeltL, et al.Vascular risk factors and dementia: 40-year follow-up of a population-based cohort. Dement Geriatr Cogn Disord2011; 31: 460–466.
45.
AnsteyKAshby-MitchellKPetersR. Updating the evidence on the association between serum cholesterol and risk of late-life dementia: review and meta-analysis. J Alzheimers Dis2017; 56: 215–228.
KannelWHjortlandMMcNamaraP, et al.Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med1976; 85: 447–452.
48.
WuLZhangXZhaoL. Human ApoE isoforms differentially modulate brain glucose and ketone body metabolism: implications for Alzheimer's disease risk reduction and early intervention. J Neurosci2018; 38: 6665.
49.
TancrediMRosengrenASvenssonA, et al.Excess mortality among persons with type 2 diabetes. N Engl J Med2015; 373: 1720–1732.
50.
US Department of Health and Human Services. National Plan to Address Alzheimer’s Disease: 2021 update. Washington, DC, 2021.
51.
CDC. Morbidity and Mortality Weekly Report (MMWR). Modifiable Risk Factors for Alzheimer Disease and Related Dementias Among Adults Aged ≥45 Years — United States, 2019, https://www.cdc.gov/mmwr/volumes/71/wr/mm7120a2.htm(accessed Nov 07 2024). 2022.
52.
ZillioxLChadrasekaranKKwanJ, et al.Diabetes and cognitive impairment. Curr Diab Rep2016; 16: 016–0775.
53.
MardenJTchetgenTKawachiI, et al.Contribution of socioeconomic status at 3 life-course periods to late-life memory function and decline: early and late predictors of dementia risk. Am J Epidemiol2017; 186: 805–814.
54.
GatzMReynoldsCAFratiglioniL, et al.Role of genes environments for explaining Alzheimer's disease. Arch Gen Psychiatry2006; 63: 168–174.
55.
PoulsenPLevinKPetersenI, et al.Heritability of insulin secretion, peripheral and hepatic insulin action, and intracellular glucose partitioning in young and old Danish twins. Diabetes2005; 54: 275–283.
56.
NicolaeDLGamazonEZhangW, et al.Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet2010; 6: e1000888.
57.
LiJMaZShiM, et al.Identification of human neuronal protein complexes reveals biochemical activities and convergent mechanisms of action in autism spectrum disorders. Cell Syst2015; 1: 361–374.
58.
ShenLLiaoLChenC, et al.Proteomics analysis of blood serums from Alzheimer's disease patients using iTRAQ labeling technology. J Alzheimers Dis2017; 56: 361–378.
59.
JohnsonECBDammerEBDuongDM, et al.Large-scale proteomic analysis of Alzheimer’s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation. Nat Med2020; 26: 769–780.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
